Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma
Veterinary and Comparative Oncology · 2023-12 · 21 (4) · 623-633
DOI: 10.1111/vco.12925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, online erschienen am 21.09.2023. Verfasst von Timothy Estabrooks und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts, USA. Hauptthemen laut MEDLINE: Hemangiosarcoma, Dog Diseases, Splenic Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PETCO Foundation, Petco Love.
Abstract (Originalsprache)
Canine hemangiosarcoma (HSA) is an aggressive cancer of endothelial cells with short survival times. Understanding the genomic landscape of HSA may aid in developing therapeutic strategies for dogs and may also inform therapies for the rare and aggressive human cancer angiosarcoma. The objectives of this study were to build a framework for leveraging real‐world genomic and clinical data that could provide the foundation for precision medicine in veterinary oncology, and to determine the relationships between genomic and clinical features in canine splenic HSA. One hundred and nine dogs with primary splenic HSA treated by splenectomy that had tumour sequencing via the FidoCure® Precision Medicine Platform targeted sequencing panel were enrolled. Patient signalment, weight, metastasis at diagnosis and overall survival time were retrospectively evaluated. The incidence of genomic alterations in individual genes and their relationship to patient variables including outcome were assessed. Somatic mutations in TP53 ( n = 44), NRAS ( n = 20) and PIK3CA ( n = 19) were most common. Survival was associated with presence of metastases at diagnosis and germline variants in SETD2 and NOTCH1 . Age at diagnosis was associated with somatic NRAS mutations and breed. TP53 and PIK3CA somatic mutations were found in larger dogs, while germline SETD2 variants were found in smaller dogs. We identified both somatic mutations and germline variants associated with clinical variables including age, breed and overall survival. These genetic changes may be useful prognostic factors and provide insight into the genomic landscape of hemangiosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts, USA.
- Tufts Medical Center, Boston, Massachusetts, USA.
- MassBio, UMass Chan Medical School, Worcester, Massachusetts, USA.
- One Health Company, Palo Alto, California, USA.
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
ORCID-Profile: Kate Megquier
Förderung
- PETCO Foundation
- Petco Love
Zitieren
APA
Estabrooks, T., Gurinovich, A., Pietruska, J., Lewis, B., Harvey, G., Post, G., Lambert, L., Miller, A., Rodrigues, L., White, M. E., Lopes, C., London, C. A., & Megquier, K. (2023). Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma. Veterinary and Comparative Oncology, 21(4), 623-633. https://doi.org/10.1111/vco.12925
Vancouver
Estabrooks T, Gurinovich A, Pietruska J, Lewis B, Harvey G, Post G, et al. Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma. Veterinary and Comparative Oncology. 2023;21(4):623-633. doi:10.1111/vco.12925
BibTeX
@article{Estabrooks2023,
author = {Estabrooks, Timothy and Gurinovich, Anastasia and Pietruska, Jodie and Lewis, Benjamin and Harvey, Garrett and Post, Gerald and Lambert, Lindsay and Miller, Aubrey and Rodrigues, Lucas and White, Michelle E and Lopes, Christina and London, Cheryl A and Megquier, Kate},
title = {Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma},
journal = {Veterinary and Comparative Oncology},
year = {2023},
volume = {21},
number = {4},
pages = {623--633},
doi = {10.1111/vco.12925}
}
EUVIMED